Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study Of The Efficacy And Safety Of SU011248 In Patients With Advanced Unresectable Neuroendocrine Tumor

NCT00056693 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00056693
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00056693 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study Of The Efficacy And Safety Of SU011248 In Patients With Advanced Unresectable Neuroendocrine Tumor
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2003
Completion date
September 30, 2006
Enrollment
107 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

neuroendocrine tumors